Stemline Therapeutics Inc. (NASDAQ:STML) shares rose 2.8% on Tuesday . The stock traded as high as $10.15 and last traded at $10.06, with a volume of 137,418 shares. The stock had previously closed at $9.79.

STML has been the topic of several recent research reports. Roth Capital restated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a report on Thursday, August 25th. Wedbush restated an “outperform” rating and set a $15.00 target price on shares of Stemline Therapeutics in a report on Tuesday, August 23rd. Jefferies Group restated a “buy” rating on shares of Stemline Therapeutics in a report on Friday, August 5th. Finally, Zacks Investment Research cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Stemline Therapeutics has a consensus rating of “Buy” and a consensus target price of $19.31.

The company’s 50-day moving average price is $8.15 and its 200-day moving average price is $6.73. The firm’s market cap is $179.68 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/stemline-therapeutics-inc-stml-stock-price-up-2-8.html

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. Stemline Therapeutics had a negative net margin of 4,419.18% and a negative return on equity of 44.59%. On average, equities analysts anticipate that Stemline Therapeutics Inc. will post ($2.11) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of STML. Paradigm Asset Management Co. LLC bought a new position in shares of Stemline Therapeutics during the second quarter worth about $141,000. State Street Corp boosted its position in shares of Stemline Therapeutics by 1.9% in the second quarter. State Street Corp now owns 220,768 shares of the biopharmaceutical company’s stock worth $1,493,000 after buying an additional 4,197 shares during the period. Rhumbline Advisers boosted its position in shares of Stemline Therapeutics by 20.9% in the second quarter. Rhumbline Advisers now owns 26,260 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 4,538 shares during the period. Franklin Resources Inc. boosted its position in shares of Stemline Therapeutics by 11.8% in the second quarter. Franklin Resources Inc. now owns 2,102,200 shares of the biopharmaceutical company’s stock worth $14,232,000 after buying an additional 222,170 shares during the period. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Stemline Therapeutics by 6.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 187,428 shares of the biopharmaceutical company’s stock worth $1,269,000 after buying an additional 11,292 shares during the period. 52.42% of the stock is owned by institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.